NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Abacus Global Management, Inc. (“Abacus”) common stock (NASDAQ: ABL). On August 30, 2022, Abacus Settlements, LLC and Longevity Market Assets, LLC and East Resources Acquisition Corporation announced a $618 million de-SPAC deal. The deal was approved by East Resources’ shareholders and closed on July 3, 2023. Abacus is an alternative asset manager specializing in life insurance products. ...

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Abacus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On J ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Abacus Life, Inc. (ABL) , which belongs to the Zacks Insurance - Life Insurance industry.This company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 17.79%.For the most recent quarter, Abacus Life, Inc. was expected to post earnin ...

Abacus Global Management (NASDAQ: ABL) is a leading financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. With a focus on longevity-based assets and personalized financial planning, Abacus leverages proprietary data analytics and decades of industry expertise to deliver innovative solutions that optimize financial outcomes for individuals and institutions worldwide. Contact: Investor Relations Robert F. Phil ...

Core Viewpoint - Abacus Global Management, Inc. is under investigation for potential securities fraud and unlawful business practices, following allegations of manipulating financial reporting to appear more profitable than it is [1][2]. Group 1: Investigation and Allegations - An investigation is being conducted on behalf of investors of Abacus Global Management regarding possible securities fraud by the company and its officers or directors [1]. - A report by Morpheus Research claims that Abacus has altered its portfolio valuation methodology to inflate profitability and uses questionable life expectancy calculations, raising concerns about the integrity of its financial practices [2]. Group 2: Market Reaction - Following the news of the investigation and the allegations, Abacus's stock price experienced a significant decline, falling by $1.64 per share, or 21.47%, closing at $6.00 per share on June 5, 2025 [3].

Core Viewpoint - Abacus Global Management, Inc. has filed a lawsuit against Coventry First LLC and its Chairman Alan Buerger, alleging a systematic campaign to disseminate false and misleading information aimed at damaging Abacus's reputation and market position [1][2][3]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Coventry and Buerger engaged in a multi-year effort to undermine Abacus's valuation practices, attempting to convince the market that Abacus overpays policyholders, leading to an overvaluation of its assets [3][4]. - Abacus asserts that Coventry's actions constitute tortious interference and defamation, as they have resorted to damaging Abacus's reputation instead of competing fairly [4]. - The lawsuit highlights that Abacus's financial practices are transparent and compliant with GAAP, contradicting Coventry's claims about Abacus's valuation methods [8][9]. Group 2: Impact of False Claims - Following a June 4, 2025 interview with Buerger, Abacus's stock dropped over 21%, resulting in a loss of more than $200 million in market capitalization due to the dissemination of false information [9][10]. - Abacus alleges that Coventry's campaign has caused substantial harm to its reputation, customer base, and investor relationships, with the company seeking hundreds of millions in damages [11][12]. - The lawsuit also points out that Coventry has a history of unsavory practices, including bid-rigging and involvement in illegal life insurance practices, which further undermines its credibility [11][12]. Group 3: Role of Short Seller - Morpheus Research is identified as a partner in disseminating Coventry's defamatory statements, with the short report released shortly after Buerger's interview, amplifying the false claims about Abacus [10][11]. - The lawsuit alleges that Morpheus's report echoed Coventry's misleading statements, contributing to the confusion among investors and market analysts [10][11].

Core Viewpoint - Abacus Global Management, Inc. has initiated an exchange offer and consent solicitation to simplify its capital structure and mitigate the potential dilutive impact of outstanding warrants [1][2]. Group 1: Exchange Offer Details - The company is offering 0.23 shares of common stock for each warrant tendered, with a total of up to 4,743,381 shares available for exchange [2]. - The offering period will last until July 29, 2025, with the possibility of extension [2]. - Holders can withdraw their tendered warrants at any time before the expiration date [2]. Group 2: Consent Solicitation - The company is soliciting consents to amend the warrant agreement, allowing for an exchange ratio of 0.207 shares per warrant, which is 10% less than the current offer [3]. - Approximately 25% of public warrants and 94% of private placement warrants have agreed to participate in the offer and consent to the amendment [3]. - An additional 25% consent from public warrant holders is needed for the amendment to be adopted [3]. Group 3: Current Capital Structure - As of June 30, 2025, there are 97,867,821 shares of common stock and 20,623,395 warrants outstanding [5]. - If all warrants are exchanged, the total shares outstanding would increase to 102,611,202, representing a 5% increase, with no warrants remaining [5]. Group 4: Regulatory Information - The offer and consent solicitation are conducted under a prospectus and Schedule TO filed with the SEC [4]. - D.F. King & Co., Inc. is the information agent, while Continental Stock Transfer & Trust Company serves as the exchange agent [6].

Core Viewpoint - Abacus Global Management, Inc. plans to conduct an exchange offer and consent solicitation for its outstanding public and private placement warrants, allowing holders to exchange warrants for shares of common stock [1][2]. Group 1: Exchange Offer Details - Each outstanding warrant is exercisable for one common share at a price of $11.50 per share [2]. - The company intends to offer 0.23 shares of common stock in exchange for each outstanding warrant tendered [2]. - The company will also solicit consents to amend the Warrant Agreement, allowing for an exchange ratio of 0.207 shares per warrant, which is 10% less than the initial offer [2]. Group 2: Regulatory and Procedural Aspects - The company expects to commence the Offer after filing a Form S-4 registration statement detailing the terms of the Offer [3].

Core Viewpoint - Abacus Global Management is facing significant pressure as its stock price has dropped over 36% in the past month due to serious allegations from Morpheus Research regarding financial misconduct and questionable accounting practices [1][5]. Group 1: Allegations and Investigations - Morpheus Research, a new investigative group with ties to Hindenburg Research, published reports accusing Abacus of manipulating its life settlements portfolio through aggressive accounting practices, leading to inflated asset values and "fake revenue" [3][4]. - Hagens Berman, a prominent law firm, has initiated its own investigation into the claims made by Morpheus Research, urging affected shareholders to report their financial losses [2][6]. - The scrutiny intensified after Morpheus's follow-up report alleged inconsistencies in Abacus's rebuttal and introduced claims of undisclosed related-party transactions [4]. Group 2: Company Response and Stock Performance - In response to the allegations, Abacus retained independent actuarial firm Lewis & Ellis to review its balance sheet and reassure investors of compliance with accounting standards [4]. - Despite the company's efforts, including a $20 million share repurchase program aimed at restoring investor confidence, the stock has continued to trade near its 52-week low [5][6]. - The stock experienced a sharp 20% drop in a single day following the initial report from Morpheus [3].

Investor Day & Longevity Summit June 12, 2025 abacusgm.com Disclaimer General. This presentation (this "Presentation") is provided solely for informational purposes. This Presentation is subject to update, completion, revision, verification and further amendment without notice. None of Abacus Global Management, Inc. (the "Company", "Abacus", Abacus Global Management", "we", "our", or "us") or its affiliates has authorized anyone to provide interested parties with additional or different information. The inf ...